Primer | Published:

Primary open-angle glaucoma

Nature Reviews Disease Primers volume 2, Article number: 16067 (2016) | Download Citation

Abstract

Glaucoma is an optic neuropathy that is characterized by the progressive degeneration of the optic nerve, leading to visual impairment. Glaucoma is the main cause of irreversible blindness worldwide, but typically remains asymptomatic until very severe. Open-angle glaucoma comprises the majority of cases in the United States and western Europe, of which, primary open-angle glaucoma (POAG) is the most common type. By contrast, in China and other Asian countries, angle-closure glaucoma is highly prevalent. These two types of glaucoma are characterized based on the anatomic configuration of the aqueous humour outflow pathway. The pathophysiology of POAG is not well understood, but it is an optic neuropathy that is thought to be associated with intraocular pressure (IOP)-related damage to the optic nerve head and resultant loss of retinal ganglion cells (RGCs). POAG is generally diagnosed during routine eye examination, which includes fundoscopic evaluation and visual field assessment (using perimetry). An increase in IOP, measured by tonometry, is not essential for diagnosis. Management of POAG includes topical drug therapies and surgery to reduce IOP, although new therapies targeting neuroprotection of RGCs and axonal regeneration are under development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. The pathophysiology and treatment of glaucoma: a review. JAMA 311, 1901–1911 (2014).

  2. 2.

    & The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262–267 (2006).

  3. 3.

    & Primary open-angle glaucoma. Lancet 363, 1711–1720 (2004).

  4. 4.

    et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121, 2081–2090 (2014).

  5. 5.

    et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br. J. Ophthalmol. 100, 86–93 (2016).

  6. 6.

    et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 266, 369–374 (1991).

  7. 7.

    et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch. Ophthalmol. 116, 1640–1645 (1998).

  8. 8.

    Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126, 487–497 (1998).

  9. 9.

    Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126, 498–505 (1998). This paper and reference 8 describe the efficacy of lowering IOP in patients with normal-tension glaucoma.

  10. 10.

    et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 109, 1090–1095 (1991).

  11. 11.

    et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 714–720; discussion 829–830 (2002). This study provides important information about risk factors for POAG obtained from a large multi-centre clinical trial that examined IOP-lowering treatment versus no treatment.

  12. 12.

    , & Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am. J. Ophthalmol. 136, 820–829 (2003).

  13. 13.

    et al. Corneal hysteresis as a risk factor for glaucoma progression: a prospective longitudinal study. Ophthalmology 120, 1533–1540 (2013). This study suggests that corneal hysteresis is a new and powerful risk factor for the development of POAG.

  14. 14.

    , , & The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology 106, 2010–2015 (1999).

  15. 15.

    , , & The association of blood pressure and primary open-angle glaucoma: a meta-analysis. Am. J. Ophthalmol. 158, 615–627.e9 (2014).

  16. 16.

    , , & Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLoS ONE 9, e102972 (2014).

  17. 17.

    , , & Incident open-angle glaucoma and blood pressure. Arch. Ophthalmol. 120, 954–959 (2002).

  18. 18.

    et al. Optic neuropathy induced by experimentally reduced cerebrospinal fluid pressure in monkeys. Invest. Ophthalmol. Vis. Sci. 55, 3067–3073 (2014).

  19. 19.

    , & Genetics of primary inherited disorders of the optic nerve: clinical applications. Cold Spring Harb. Perspect. Med. 5, a017277 (2015).

  20. 20.

    The morphological difference between glaucoma and other optic neuropathies. J. Neuroophthalmol. 35, S8–S21 (2015).

  21. 21.

    Biomechanical assessment in models of glaucomatous optic neuropathy. Exp. Eye Res. 141, 125–138 (2015).

  22. 22.

    , , , & Absence of transient receptor potential vanilloid-1 accelerates stress-induced axonopathy in the optic projection. J. Neurosci. 34, 3161–3170 (2014).

  23. 23.

    , , , & Current concepts in the pathophysiology of glaucoma. Indian J. Ophthalmol. 57, 257–266 (2009).

  24. 24.

    , , & Vascular dysregulation: a principal risk factor for glaucomatous damage? J. Glaucoma 8, 212–219 (1999).

  25. 25.

    , , & The potential value of natural antioxidative treatment in glaucoma. Surv. Ophthalmol. 53, 479–505 (2008).

  26. 26.

    et al. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest. Ophthalmol. Vis. Sci. 48, 4580–4589 (2007).

  27. 27.

    & Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog. Brain Res. 173, 495–510 (2008).

  28. 28.

    & Immunoregulation of retinal ganglion cell fate in glaucoma. Exp. Eye Res. 88, 825–830 (2009).

  29. 29.

    & The immune system and glaucoma. Curr. Opin. Ophthalmol. 15, 80–84 (2004).

  30. 30.

    et al. Does autoimmunity play a part in the pathogenesis of glaucoma? Prog. Retin. Eye Res. 36, 199–216 (2013).

  31. 31.

    et al. Müller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 25, 397–424 (2006).

  32. 32.

    et al. Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia 58, 780–789 (2010).

  33. 33.

    & Reactive nonproliferative gliosis predominates in a chronic mouse model of glaucoma. Glia 55, 942–953 (2007).

  34. 34.

    & Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist 9, 485–495 (2003).

  35. 35.

    , & Intraocular pressure and the mechanisms involved in resistance of the aqueous humor flow in the trabecular meshwork outflow pathways. Prog. Mol. Biol. Transl Sci. 134, 301–314 (2015).

  36. 36.

    , & Mitochondrial defects and dysfunction in calcium regulation in glaucomatous trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 49, 4912–4922 (2008).

  37. 37.

    Morphological changes in glaucomatous eyes and the role of TGFβ2 for the pathogenesis of the disease. Exp. Eye Res. 81, 1–4 (2005).

  38. 38.

    , & Mini-review: impaired axonal transport and glaucoma. Curr. Eye Res. 41, 273–283 (2016).

  39. 39.

    et al. Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration. Exp. Eye Res. 90, 168–183 (2010).

  40. 40.

    , & Optic nerve hydropic axonal degeneration and blocked retrograde axoplasmic transport: histopathologic features in human high-pressure secondary glaucoma. Arch. Ophthalmol. 125, 347–353 (2007).

  41. 41.

    , , , & Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41, 764–774 (2000).

  42. 42.

    et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44, 4357–4365 (2003).

  43. 43.

    et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 50, 2194–2200 (2009).

  44. 44.

    , , & Visual field defect and perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open-angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 236, 80–85 (1998).

  45. 45.

    , , & Peripapillary retinal blood flow in normal tension glaucoma. Br. J. Ophthalmol. 83, 466–469 (1999).

  46. 46.

    et al. Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Curr. Eye Res. 37, 1–11 (2012).

  47. 47.

    et al. Retinal ganglion cells: energetics, compartmentation, axonal transport, cytoskeletons and vulnerability. Prog. Retin. Eye Res. 36, 217–246 (2013).

  48. 48.

    et al. Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J. Neurosci. 30, 5644–5652 (2010).

  49. 49.

    et al. Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts. Invest. Ophthalmol. Vis. Sci. 53, 2431–2437 (2012).

  50. 50.

    et al. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest. Ophthalmol. Vis. Sci. 49, 4903–4911 (2008).

  51. 51.

    et al. Comparative quantitative study of astrocytes and capillary distribution in optic nerve laminar regions. Exp. Eye Res. 121, 11–22 (2014).

  52. 52.

    , , , & Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma 11, 474–480 (2002).

  53. 53.

    et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest. Ophthalmol. Vis. Sci. 45, 2625–2639 (2004).

  54. 54.

    et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest. Ophthalmol. Vis. Sci. 45, 2640–2651 (2004).

  55. 55.

    Align Technology. Align Technology announces fourth quarter and fiscal 2007 results. Align Tech (2008).

  56. 56.

    The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog. Retin. Eye Res. 19, 297–321 (2000).

  57. 57.

    , & Morphology of astrocytes in a glaucomatous optic nerve. Invest. Ophthalmol. Vis. Sci. 54, 909–917 (2013).

  58. 58.

    , , , & Extracellular matrix changes of the optic nerve lamina cribrosa in monkey eyes with experimentally chronic glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 230, 421–427 (1992).

  59. 59.

    et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36, 774–786 (1995).

  60. 60.

    , , , & TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. 115, 1031–1035 (1997).

  61. 61.

    et al. Does elevated intraocular pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma? Exp. Eye Res. 89, 921–933 (2009).

  62. 62.

    , , & Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. Vis. Neurosci. 24, 127–139 (2007).

  63. 63.

    et al. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer’s disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv. Ophthalmol. 48, S25–S37 (2003).

  64. 64.

    et al. P16INK4a upregulation mediated by SIX6 defines retinal ganglion cell pathogenesis in glaucoma. Mol. Cell 59, 931–940 (2015). This study highlights the role of SIX6 in RGC death in glaucoma.

  65. 65.

    et al. Enhanced optineurin E50K–TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma. Hum. Mol. Genet. 22, 3559–3567 (2013).

  66. 66.

    et al. TBK1 gene duplication and normal-tension glaucoma. JAMA Ophthalmol. 132, 544–548 (2014). This paper describes TBK1 mutations in normal-tension glaucoma.

  67. 67.

    & Defects in autophagy caused by glaucoma-associated mutations in optineurin. Exp. Eye Res. 144, 54–63 (2016).

  68. 68.

    & Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc. Natl Acad. Sci. USA 111, E4439–E4448 (2014).

  69. 69.

    et al. Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma. J. Stem Cell Res. Ther. 3, 161 (2014).

  70. 70.

    , & Glaucoma: thinking in new ways — a role for autonomous axonal self-destruction and other compartmentalised processes? Prog. Retin. Eye Res. 24, 639–662 (2005).

  71. 71.

    , , & Intrinsic axonal degeneration pathways are critical for glaucomatous damage. Exp. Neurol. 246, 54–61 (2013).

  72. 72.

    et al. Tracking dendritic shrinkage of retinal ganglion cells after acute elevation of intraocular pressure. Invest. Ophthalmol. Vis. Sci. 52, 7205–7212 (2011).

  73. 73.

    et al. Long-term in vivo imaging and measurement of dendritic shrinkage of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 52, 1539–1547 (2011).

  74. 74.

    , , , & Synapse loss and dendrite remodeling in a mouse model of glaucoma. PLoS ONE 10, e0144341 (2015).

  75. 75.

    , , , & Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J. Cell Biol. 171, 313–325 (2005).

  76. 76.

    et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164–1178 (2007).

  77. 77.

    The case for autoimmunity in glaucoma. Exp. Eye Res. 93, 187–190 (2011).

  78. 78.

    Toward understanding the optic neuropathy of glaucoma. Arch. Ophthalmol. 116, 1102–1103 (1998).

  79. 79.

    Glaucoma genes and mechanisms. Prog. Mol. Biol. Transl Sci. 134, 315–342 (2015). This is a recent review on genes that are associated with glaucoma, including POAG and normal-tension glaucoma.

  80. 80.

    et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat. Genet. 48, 189–194 (2016). This is the most recent genome-wide association study for POAG that identified three new loci.

  81. 81.

    et al. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. Nat. Genet. 46, 1126–1130 (2014).

  82. 82.

    et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet. 8, e1002654 (2012).

  83. 83.

    et al. Variations in the myocilin gene in patients with open-angle glaucoma. Arch. Ophthalmol. 120, 1189–1197 (2002).

  84. 84.

    et al. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J. Clin. Invest. 121, 3542–3553 (2011). This study shows that a chemical chaperone can alleviate the increase in IOP caused by a MYOC missense mutation.

  85. 85.

    et al. Clinical features and course of patients with glaucoma with the E50K mutation in the optineurin gene. Invest. Ophthalmol. Vis. Sci. 46, 2816–2822 (2005). This is an important study showing that the OPTN E50K mutation causes normal-tension glaucoma.

  86. 86.

    et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. Hum. Mol. Genet. 20, 2482–2494 (2011). This analysis identifies 12p14 duplication in patients with normal-tension glaucoma.

  87. 87.

    , , & E50K-OPTN-induced retinal cell death involves the Rab GTPase-activating protein, TBC1D17 mediated block in autophagy. PLoS ONE 9, e95758 (2014).

  88. 88.

    & (eds) Angle Closure and Angle Closure Glaucoma (Kugler Publications, 2006).

  89. 89.

    , , , & Mapping structural to functional damage in glaucoma with standard automated perimetry and confocal scanning laser ophthalmoscopy. Am. J. Ophthalmol. 125, 436–446 (1998).

  90. 90.

    , , , & Detection of glaucoma using scanning laser polarimetry with enhanced corneal compensation. Invest. Ophthalmol. Vis. Sci. 48, 3146–3153 (2007).

  91. 91.

    et al. Comparability of retinal nerve fiber layer thickness measurements of optical coherence tomography instruments. Invest. Ophthalmol. Vis. Sci. 46, 1280–1285 (2005).

  92. 92.

    , , , & Comparison of the diagnostic accuracies of the Spectralis, Cirrus, and RTVue optical coherence tomography devices in glaucoma. Ophthalmology 118, 1334–1339 (2011).

  93. 93.

    et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: analysis of the retinal nerve fiber layer map for glaucoma detection. Ophthalmology 117, 1684–1691 (2010).

  94. 94.

    et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: pattern of RNFL defects in glaucoma. Ophthalmology 117, 2337–2344 (2010).

  95. 95.

    , , , & Use of progressive glaucomatous optic disk change as the reference standard for evaluation of diagnostic tests in glaucoma. Am. J. Ophthalmol. 139, 1010–1018 (2005).

  96. 96.

    et al. Impact of age-related change of retinal nerve fiber layer and macular thicknesses on evaluation of glaucoma progression. Ophthalmology 120, 2485–2492 (2013).

  97. 97.

    et al. Enhanced detection of open-angle glaucoma with an anatomically accurate optical coherence tomography-derived neuroretinal rim parameter. Ophthalmology 120, 535–543 (2013).

  98. 98.

    , , , & Estimating lead time gained by optical coherence tomography in detecting glaucoma before development of visual field defects. Ophthalmology 122, 2002–2009 (2015).

  99. 99.

    , , & Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch. Ophthalmol. 111, 645–650 (1993).

  100. 100.

    , & Frequency doubling technology perimetry abnormalities as predictors of glaucomatous visual field loss. Am. J. Ophthalmol. 137, 863–871 (2004).

  101. 101.

    et al. Identifying glaucomatous vision loss with visual-function-specific perimetry in the diagnostic innovations in glaucoma study. Invest. Ophthalmol. Vis. Sci. 47, 3381–3389 (2006).

  102. 102.

    , , & The ability of short-wavelength automated perimetry to predict conversion to glaucoma. Ophthalmology 117, 30–34 (2010).

  103. 103.

    et al. Comparison of standard automated perimetry, frequency-doubling technology perimetry, and short-wavelength automated perimetry for detection of glaucoma. Invest. Ophthalmol. Vis. Sci. 52, 7325–7331 (2011).

  104. 104.

    , , & (eds) Intraocular Pressure (Kugler Publications, 2007).

  105. 105.

    & Genetic testing for inherited eye disease: who benefits? JAMA Ophthalmol. 131, 1265–1266 (2013). A commentary on the benefit of genetic testing for patients with inherited eye diseases, including glaucoma.

  106. 106.

    et al. Predictive genetic testing experience for myocilin primary open-angle glaucoma using the Australian and New Zealand Registry of Advanced Glaucoma. Genet. Med. 16, 558–563 (2014).

  107. 107.

    et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 53, 1557–1565 (2012).

  108. 108.

    et al. (eds) Progression of Glaucoma (Kugler Publications, 2011).

  109. 109.

    et al. Agreement among glaucoma specialists in assessing progressive disc changes from photographs in open-angle glaucoma patients. Am. J. Ophthalmol. 147, 39–44.e1 (2009).

  110. 110.

    et al. Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning: a 5-year prospective study. Ophthalmology 123, 1201–1210 (2016).

  111. 111.

    et al. Prediction of functional loss in glaucoma from progressive optic disc damage. Arch. Ophthalmol. 127, 1250–1256 (2009).

  112. 112.

    et al. Retinal nerve fiber layer atrophy is associated with visual field loss over time in glaucoma suspect and glaucomatous eyes. Am. J. Ophthalmol. 155, 73–82.e1 (2013).

  113. 113.

    et al. Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma. Ophthalmology 121, 100–109 (2014).

  114. 114.

    et al. A combined index of structure and function for staging glaucomatous damage. Arch. Ophthalmol. 130, 1107–1116 (2012).

  115. 115.

    , & Burden of undetected and untreated glaucoma in the United States. Am. J. Ophthalmol. 158, 1121–1129.e1 (2014).

  116. 116.

    et al. Prevalence, risk factors, and visual features of undiagnosed glaucoma: the Singapore Epidemiology of Eye Diseases Study. JAMA Ophthalmol. 133, 938–946 (2015).

  117. 117.

    , & (eds) Glaucoma Screening (Kugler Publications, 2008).

  118. 118.

    et al. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest. Ophthalmol. Vis. Sci. 49, 5373–5385 (2008).

  119. 119.

    , & The cost-effectiveness analysis of teleglaucoma screening device. PLoS ONE 10, e0137913 (2015).

  120. 120.

    et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120, 1268–1279 (2002).

  121. 121.

    et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol. Scand. 81, 286–293 (2003).

  122. 122.

    American Academy of Opthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. AAO (2010).

  123. 123.

    et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 385, 1295–1304 (2015). This is the first placebo-controlled trial to demonstrate the efficacy of lowering IOP in glaucoma.

  124. 124.

    et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 701–713; discussion 829–830 (2002).

  125. 125.

    et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 116, 200–207 (2009).

  126. 126.

    The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130, 429–440 (2000).

  127. 127.

    , , , & Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118, 1766–1773 (2011).

  128. 128.

    , , & Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J. Glaucoma 15, 124–130 (2006).

  129. 129.

    , & Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11, 541–559 (2012).

  130. 130.

    et al. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch. Ophthalmol. 119, 853 (2001).

  131. 131.

    & Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp. Eye Res. 88, 786–791 (2009).

  132. 132.

    , & Intraocular pressure measurements throughout the 24 h. Curr. Opin. Ophthalmol. 20, 79–83 (2009).

  133. 133.

    , , & Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 117, 2075–2079 (2010).

  134. 134.

    , , & Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 116, 449–454 (2009).

  135. 135.

    et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology 116, 2286–2293 (2009).

  136. 136.

    , , , & Australian and New Zealand Glaucoma Interest Group. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin. Experiment. Ophthalmol. 43, 214–220 (2015).

  137. 137.

    , , , & Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv. Ophthalmol. 60, 36–50 (2015).

  138. 138.

    Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia. JAMA Ophthalmol. 131, 321–327 (2013).

  139. 139.

    et al. Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes. Eye (Lond.) 23, 2194–2199 (2009).

  140. 140.

    et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials 16, 406 (2015).

  141. 141.

    , & Developments in laser trabeculoplasty. Br. J. Ophthalmol. 100, 94–97 (2016).

  142. 142.

    , , & Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials. Clin. Experiment. Ophthalmol. 41, 798–806 (2013).

  143. 143.

    , , , & Twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology 119, 694–702 (2012).

  144. 144.

    , , & Outcomes of glaucoma reoperations in the tube versus trabeculectomy (TVT) study. Am. J. Ophthalmol. 157, 1179–1189.e2 (2014).

  145. 145.

    et al. Aqueous shunts in glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology 115, 1089–1098 (2008).

  146. 146.

    et al. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. Am. J. Ophthalmol. 153, 789–803.e2 (2012).

  147. 147.

    et al. Cataract. Nat. Rev. Dis. Primers 1, 15014 (2015).

  148. 148.

    , , , & Clinical results of ab interno trabeculotomy using the trabectome for open-angle glaucoma: the Mayo Clinic series in Rochester, Minnesota. Am. J. Ophthalmol. 157, 1325–1326 (2014).

  149. 149.

    , , , & Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology 118, 459–467 (2011).

  150. 150.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  151. 151.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  152. 152.

    Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr. Opin. Ophthalmol. 20, 92–98 (2009). This is a comprehensive review of QOL issues in patients with glaucoma.

  153. 153.

    , , , & Binocular visual field impairment in glaucoma and at-fault motor vehicle collisions. J. Glaucoma 24, 138–143 (2015).

  154. 154.

    , & Inferior field loss increases rate of falls in older adults with glaucoma. Optom. Vis. Sci. 88, 1275–1282 (2011).

  155. 155.

    , , & Driving status and risk of entry into long-term care in older adults. Am. J. Public Health 96, 1254–1259 (2006).

  156. 156.

    , , , & Glaucoma and on-road driving performance. Invest. Ophthalmol. Vis. Sci. 49, 3035–3041 (2008).

  157. 157.

    et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 46, 4437–4441 (2005).

  158. 158.

    et al. Predicting risk of motor vehicle collisions in patients with glaucoma: a longitudinal study. PLoS ONE 10, e0138288 (2015).

  159. 159.

    & Useful field of view test. Gerontology 60, 315–318 (2014).

  160. 160.

    et al. Visual processing impairment and risk of motor vehicle crash among older adults. JAMA 279, 1083–1088 (1998).

  161. 161.

    , , , & Relationship between motor vehicle collisions and results of perimetry, useful field of view, and driving simulation in drivers with glaucoma. Transl Vis. Sci. Technol. 4, 5 (2015).

  162. 162.

    et al. A portable platform for evaluation of visual performance in glaucoma patients. PLoS ONE 10, e0139426 (2015).

  163. 163.

    , & Driving habits in glaucoma patients. J. Fr. Ophtalmol. 35, 235–241 (2012).

  164. 164.

    , , , & Driving cessation and driving limitation in glaucoma: the Salisbury Eye Evaluation Project. Ophthalmology 116, 1846–1853 (2009).

  165. 165.

    et al. Visual impairment, causes of vision loss, and falls: the singapore malay eye study. Invest. Ophthalmol. Vis. Sci. 49, 528–533 (2008).

  166. 166.

    , , , & Risk of falls and motor vehicle collisions in glaucoma. Invest. Ophthalmol. Vis. Sci. 48, 1149–1155 (2007).

  167. 167.

    et al. Evaluation of postural control in patients with glaucoma using a virtual reality environment. Ophthalmology 122, 1131–1138 (2015). This is the first study to evaluate the application of a virtual-reality-based strategy for the assessment of disability in glaucoma.

  168. 168.

    et al. Evaluation of quality of life and priorities of patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 49, 1907–1915 (2008).

  169. 169.

    , , & Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom. Vis. Sci. 84, 797–808 (2007).

  170. 170.

    et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology 122, 293–301 (2015). This is the first investigation of the association between rates of disease progression and longitudinal changes in QOL in glaucoma.

  171. 171.

    et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 115, 941–948.e1 (2008).

  172. 172.

    et al. Association between rates of binocular visual field loss and vision-related quality of life in patients with glaucoma. JAMA Ophthalmol. 131, 486–494 (2013).

  173. 173.

    et al. Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma. JAMA Ophthalmol. 133, 384–390 (2015).

  174. 174.

    Australian New Zealand Clinical Trials Registry. Glaucoma Initial Treatment Study (GITS): a comparison of eye drops versus laser treatment. ANZCTR (2011).

  175. 175.

    & Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function. Invest. Ophthalmol. Vis. Sci. 52, 7842–7851 (2011).

  176. 176.

    et al. (eds) Medical Treatment of Glaucoma: Consensus Series — 7 (Kugler Publications, 2010).

  177. 177.

    et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 51, 2051–2059 (2010).

  178. 178.

    et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc. Natl Acad. Sci. USA 109, 9149–9154 (2012).

  179. 179.

    , & Effective Perimetry: The Field Analyzer Primer (Carl-Zeiss Meditec, 2012).

  180. 180.

    et al. Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma. Nat. Genet. 46, 1115–1119 (2014).

  181. 181.

    et al. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nat. Genet. 46, 1120–1125 (2014).

  182. 182.

    Degenerative ataxias, from genes to therapies: the 2015 Cotzias Lecture. Neurology 86, 2284–2290 (2016).

  183. 183.

    , , , & The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway. Autophagy 12, 1406–1408 (2016).

  184. 184.

    et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat. Genet. 42, 906–909 (2010).

  185. 185.

    et al. Exome array analysis identifies CAV1/CAV2 as a susceptibility locus for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 56, 544–551 (2015).

  186. 186.

    et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. Hum. Mol. Genet. 20, 4707–4713 (2011).

  187. 187.

    et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat. Genet. 43, 574–578 (2011).

  188. 188.

    et al. A genome-wide association study of optic disc parameters. PLoS Genet. 6, e1000978 (2010).

  189. 189.

    et al. Hypo- and hypermorphic FOXC1 mutations in dominant glaucoma: transactivation and phenotypic variability. PLoS ONE 10, e0119272 (2015).

  190. 190.

    et al. Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet. 8, e1002611 (2012).

  191. 191.

    et al. Discovery and functional annotation of SIX6 variants in primary open-angle glaucoma. PLoS Genet. 10, e1004372 (2014). This study identifies pathogenetic SIX6 mutations using a zebrafish complementation assay.

  192. 192.

    et al. Quantitative trait locus analysis of SIX1SIX6 with retinal nerve fiber layer thickness in individuals of European descent. Am. J. Ophthalmol. 160, 123–130.e1 (2015).

  193. 193.

    et al. A common variant near TGFBR3 is associated with primary open angle glaucoma. Hum. Mol. Genet. 24, 3880–3892 (2015).

  194. 194.

    et al. TMCO1 is an ER Ca2+ load-activated Ca2+ channel. Cell 165, 1454–1466 (2016).

  195. 195.

    et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F2α–isopropyl ester treatment. Arch. Ophthalmol. 119, 1165–1170 (2001).

  196. 196.

    , & The mechanism of action of prostaglandins on uveoscleral outflow. Curr. Opin. Ophthalmol. 11, 112–115 (2000).

  197. 197.

    , , & in Medical Treatment of Glaucoma: Consensus Series — 7 (eds Weinreb, R. N. et al.) 31–36 (Kugler Publications, 2010).

  198. 198.

    in Medical Treatment of Glaucoma: Consensus Series — 7 (eds Weinreb, R. N. et al.) 37–43 (Kugler Publications, 2010).

  199. 199.

    , , & in Medical Treatment of Glaucoma: Consensus Series — 7 (eds Weinreb, R. N. et al.) 51–58 (Kugler Publications, 2010).

Download references

Acknowledgements

R.N.W. has received research support from the National Eye Institute. D.S.F. has received research support from the US NIH and the US Centers of Disease Control and Prevention. J.L.W. has received research support from the NIH, March of Dimes and Research to Prevent Blindness.

Author information

Affiliations

  1. Shiley Eye Institute, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.

    • Robert N. Weinreb
    •  & Felipe A. Medeiros
  2. Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China.

    • Christopher K. S. Leung
  3. Department of Ophthalmology, Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia.

    • Jonathan G. Crowston
  4. Dana Center for Preventive Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USA.

    • David S. Friedman
  5. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.

    • Janey L. Wiggs
  6. Department of Ophthalmology and Cambridge NIHR Biomedical Research Centre, University of Cambridge, Cambridge, UK.

    • Keith R. Martin

Authors

  1. Search for Robert N. Weinreb in:

  2. Search for Christopher K. S. Leung in:

  3. Search for Jonathan G. Crowston in:

  4. Search for Felipe A. Medeiros in:

  5. Search for David S. Friedman in:

  6. Search for Janey L. Wiggs in:

  7. Search for Keith R. Martin in:

Contributions

Introduction (R.N.W.); Epidemiology (D.S.F.); Mechanisms/pathophysiology (K.R.M. and J.L.W.); Diagnosis, screening and prevention (C.K.S.L. and R.N.W.); Management (J.G.C.); Quality of life (F.A.M.); Outlook (R.N.W. and J.G.C.); Overview of the Primer (R.N.W.).

Competing interests

R.N.W. has received personal fees from Allergan, Alcon, Ametek, Bausch + Lomb, Carl-Zeiss Meditec, ForSight Vision5 and Topcon, and has received research support from Genentech and Quark, in addition to research equipment from Heidelberg Engineering, Konan, Optovue and Topcon. C.K.S.L. has received research support from Carl-Zeiss Meditec and Topcon. J.G.C. has served on advisory committees for Allergan, Alcon, CERA Technologies, Pfizer, Polyactiva and Seagull Technologies. F.A.M. has received personal fees from Carl-Zeiss Meditec, Heidelberg Engineering, Ametek, Alcon and Allergan, and research support from Carl-Zeiss Meditec, Heidelberg Engineering, Topcon, Ametek, Bausch + Lomb, Allergan and Sensimed. D.S.F. has received consulting fees from Nidek and ForSight Vision5. K.R.M. has received personal fees from Allergan, Bausch + Lomb, MSD and Santen. J.L.W. declares no competing interests.

Corresponding author

Correspondence to Robert N. Weinreb.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrdp.2016.67

Further reading